Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Losartan dose-ranging study in pediatric hypertension
2008-004732-20Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of losartan in hypertension (HTN) (3 arms), sponsored by Merck & Co. Primary endpoint: Change in sitting systolic blood pressure after 21 days compared with baseline as a function of dose. Started Oct 2008; status: completed.
02
Drugs
losartan
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on 2008-004732-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004732-20.